INmune Bio Inc (INMB)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $32.51M
Last updated: Nov 17, 2026 at 11:05 AM ET
INmune Bio Inc (INMB) Competitors
The companies most similar to INmune Bio are ImageneBio (IMA), Instil Bio (TIL) and Mink Therapeutics (INKT). By market cap, INmune Bio ranks 8th of the 13 companies on this page; Immunic (IMUX) is the largest at $102.61M.
Peer Comparison
INMB's revenue growth of 257.1% is above the peer median of 0.0%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| INmune Bio (INMB) | $32.51M | N/A | N/A | 0.0% | N/A | 257.1% | 0.00% |
| ImageneBio, Inc. (IMA) | $43.22M | N/A | 68.5x | 0.0% | N/A | 0.0% | 0.00% |
| Instil Bio Inc. (TIL) | $41.23M | N/A | N/A | 0.0% | -11.9% | 0.0% | 0.00% |
| Mink Therapeutics Inc (INKT) | $47.95M | N/A | 236.3x | 0.0% | N/A | 0.0% | 0.00% |
| Estrella Immunopharma Inc. (ESLA) | $22.36M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Connect Biopharma Holdings Ltd (CNTB) | $42.65M | N/A | 13.6x | 0.0% | N/A | 5667.0% | 0.00% |
| NextCure Inc (NXTC) | $29.31M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| iBio, Inc. Common Stock (IBIO) | $51.55M | N/A | 735.4x | 0.0% | N/A | 975.0% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Barinthus Biotherapeutics plc (BRNS) | $30.23M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| ProMIS Neurosciences Inc. (PMN) | $29.60M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Immutep Ltd ADR (IMMP) | $25.64M | N/A | 2.2x | 0.0% | N/A | 633.0% | 0.00% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $36.15M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Peer median | $38.69M | N/A | 68.5x | 0.0% | -11.9% | 0.0% | 0.00% |
Similar Companies
These are the 12 companies most similar to INmune Bio, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| ImageneBio, Inc. (IMA) | ImageneBio, Inc., a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. | IMA competitors |
| Instil Bio Inc. (TIL) | Instil Bio, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer patients. | TIL competitors |
| Mink Therapeutics Inc (INKT) | MiNK Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of allogeneic... | INKT competitors |
| Estrella Immunopharma Inc. (ESLA) | Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. | ESLA competitors |
| Connect Biopharma Holdings Ltd (CNTB) | Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, is focused on the discovery and development of immune modulators... | CNTB competitors |
| NextCure Inc (NXTC) | NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other... | NXTC competitors |
| iBio, Inc. Common Stock (IBIO) | iBio, Inc., a biotech company, provides contract development and manufacturing services to outside partners and customers in the United States. | IBIO competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Barinthus Biotherapeutics plc (BRNS) | Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in developing novel T cell immunotherapeutics to guide the immune system... | BRNS competitors |
| ProMIS Neurosciences Inc. (PMN) | ProMIS Neurosciences Inc. is a pioneering biotechnology company focused on the development of innovative therapeutic solutions for neurodegenerative diseases... | PMN competitors |
| Immutep Ltd ADR (IMMP) | Immutep Limited, a biotechnology company, is dedicated to the research and development of pharmaceutical candidates. | |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human... | TELO competitors |
Frequently Asked Questions About INMB
Who are INmune Bio's main competitors?
The companies most similar to INmune Bio include ImageneBio (IMA), Instil Bio (TIL), Mink Therapeutics (INKT), Estrella Immunopharma (ESLA) and Connect Biopharma Holdings (CNTB), listed from the closest match.
Who is INmune Bio's biggest competitor?
Immunic (IMUX) is the largest of the similar companies at $102.61M; ImageneBio (IMA) is the closest match by business profile, size, sector and industry.
How does INMB stock compare with its competitors?
INMB's net margin is 0.0% against a peer median of 0.0%.
Which of INmune Bio's competitors pays a higher dividend?
INmune Bio pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is INmune Bio bigger than its competitors?
No. INmune Bio is 8th by market cap among the 13 companies on this page; the largest is Immunic (IMUX) at $102.61M.
INMB pages: Overview, Earnings, Forecast, Financials, Competitors